

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2006**

**OTHER (INCOME)/EXPENSE, NET (millions of dollars)**

|                    | 3Q `06            | 3Q `05           | YTD 2006          | YTD 2005       |
|--------------------|-------------------|------------------|-------------------|----------------|
| INTEREST INCOME    | \$ (195.0)        | \$ (122.3)       | \$ (564.6)        | \$ (314.8)     |
| INTEREST EXPENSE   | 87.7              | 99.6             | 277.8             | 277.2          |
| EXCHANGE GAINS     | (11.5)            | (7.4)            | (4.5)             | (16.5)         |
| MINORITY INTERESTS | 30.7              | 30.9             | 90.7              | 91.6           |
| Other, net         | (46.6)            | (25.5)           | (104.8)           | (21.7)         |
| <b>TOTAL</b>       | <b>\$ (134.7)</b> | <b>\$ (24.7)</b> | <b>\$ (305.4)</b> | <b>\$ 15.8</b> |

**JOINT VENTURE SALES DETAIL (millions of dollars)**

All sales reported here are end-market JV sales, presented on a "NET" basis.

| <b>Merial</b>                        | 3Q `06          | 3Q `05          | YTD 2006          | YTD 2005          |
|--------------------------------------|-----------------|-----------------|-------------------|-------------------|
| IVOMEK, HEARTGARD, other avermectins | \$ 111.5        | \$ 123.9        | \$ 362.0          | \$ 350.2          |
| FRONTLINE                            | 217.1           | 199.4           | 732.6             | 613.7             |
| Biologicals                          | 143.5           | 133.1           | 435.6             | 384.2             |
| Other Animal Health                  | 61.4            | 56.7            | 175.4             | 172.1             |
| <b>TOTAL MERIAL SALES</b>            | <b>\$ 533.5</b> | <b>\$ 513.1</b> | <b>\$ 1,705.6</b> | <b>\$ 1,520.2</b> |

| <b>Sanofi Pasteur-MSD</b>     | 3Q `06          | 3Q `05          | YTD 2006        | YTD 2005        |
|-------------------------------|-----------------|-----------------|-----------------|-----------------|
| HEPATITIS VACCINES            | \$ 17.8         | \$ 21.2         | \$ 54.3         | \$ 66.1         |
| VIRAL VACCINES                | 24.9            | 22.3            | 69.6            | 60.9            |
| Other Vaccines                | 187.0           | 256.2           | 455.6           | 539.0           |
| <b>TOTAL SANOFI-MSD SALES</b> | <b>\$ 229.7</b> | <b>\$ 299.7</b> | <b>\$ 579.5</b> | <b>\$ 666.0</b> |

| <b>Merck / Schering-Plough Collaboration</b> | 3Q `06            | 3Q `05          | YTD 2006          | YTD 2005          |
|--|-------------------|-----------------|-------------------|-------------------|
| VYTORIN (Worldwide)                          | \$ 526.6          | \$ 273.7        | \$ 1,402.4        | \$ 673.4          |
| ZETIA (Worldwide)                            | 501.9             | 356.0           | 1,392.7           | 1,005.3           |
| <b>TOTAL</b>                                 | <b>\$ 1,028.5</b> | <b>\$ 629.7</b> | <b>\$ 2,795.1</b> | <b>\$ 1,678.7</b> |

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**THIRD QUARTER**  
**2006**

**NET PRODUCT SALES DETAIL (millions of dollars)**

| PRODUCT                       | 3Q '06 vs. 3Q '05 |             |               |            |                  |               |
|-------------------------------|-------------------|-------------|---------------|------------|------------------|---------------|
|                               | TOTAL<br>% CHG    | TOTAL<br>\$ | U.S.<br>% CHG | U.S.<br>\$ | Foreign<br>% CHG | Foreign<br>\$ |
| COZAAR / HYZAAR               | 8%                | 813         | 19%           | 320        | 2%               | 494           |
| FOSAMAX                       | -1%               | 771         | 7%            | 493        | -12%             | 278           |
| SINGULAIR                     | 25%               | 868         | 29%           | 631        | 17%              | 237           |
| ZOCOR                         | -65%              | 371         | -80%          | 152        | -22%             | 219           |
| Other Reported Products:      |                   |             |               |            |                  |               |
| AGGRASTAT                     | 6%                | 22          | N/A           | -          | 6%               | 22            |
| ARCOXIA                       | 18%               | 66          | N/A           | -          | 18%              | 66            |
| CANCIDAS                      | -11%              | 127         | -43%          | 46         | 32%              | 81            |
| COSOPT / TRUSOPT              | 22%               | 191         | 40%           | 92         | 9%               | 99            |
| CRIVAN / STOCRIN              | -9%               | 83          | -27%          | 7          | -7%              | 76            |
| EMEND                         | 84%               | 41          | 73%           | 32         | *                | 9             |
| INVANZ                        | 47%               | 37          | 42%           | 22         | 56%              | 15            |
| MAXALT                        | 14%               | 105         | 14%           | 70         | 14%              | 35            |
| PRIMAXIN                      | -                 | 182         | 8%            | 55         | -3%              | 127           |
| PROPECIA                      | 33%               | 89          | 25%           | 36         | 39%              | 53            |
| PROSCAR                       | -32%              | 127         | -66%          | 34         | 6%               | 94            |
| TIMOPTIC / TIMOPTIC XE        | -11%              | 31          | -13%          | 2          | -11%             | 29            |
| VASOTEC / VASERETIC           | -10%              | 134         | N/A           | -          | -10%             | 134           |
| HEPATITIS VACCINES            | 6%                | 69          | 1%            | 55         | 32%              | 13            |
| VIRAL VACCINES <sup>(1)</sup> | *                 | 390         | *             | 368        | 45%              | 21            |
| OTHER VACCINES                | 11%               | 97          | 15%           | 82         | -8%              | 15            |

\* 100% or over  
N/A - Not Applicable

<sup>(1)</sup> Includes new vaccine sales: Gardasil \$70m, RotaTeq \$62m, ProQuad \$84m, and Zostavax \$10m.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

|                            | 3Q '06   | % CHG. | VOL | PX | FX  |
|----------------------------|----------|--------|-----|----|-----|
| TOTAL PHARMACEUTICAL SALES | \$ 5,410 | -      | 1   | -2 | 1   |
| U.S. (\$ MM)               | 3,244    | -      | 2   | -2 | N/A |
| Foreign (\$ MM)            | 2,166    | -1%    | -   | -2 | 2   |

**MERCK & CO., INC.**  
**OTHER FINANCIAL DISCLOSURES**  
**SEPTEMBER YEAR-TO-DATE**  
**2006**

**NET PRODUCT SALES DETAIL (millions of dollars)**

| PRODUCT                       | SEPTEMBER YTD `06 vs. SEPTEMBER YTD `05 |             |               |            |                  |               |
|-------------------------------|---|-------------|---------------|------------|------------------|---------------|
|                               | TOTAL<br>% CHG                          | TOTAL<br>\$ | U.S.<br>% CHG | U.S.<br>\$ | Foreign<br>% CHG | Foreign<br>\$ |
| COZAAR / HYZAAR               | 2%                                      | 2,298       | 8%            | 821        | -1%              | 1,477         |
| FOSAMAX                       | -2%                                     | 2,345       | 9%            | 1,466      | -17%             | 879           |
| SINGULAIR                     | 21%                                     | 2,619       | 28%           | 1,887      | 7%               | 732           |
| ZOCOR                         | -27%                                    | 2,424       | -26%          | 1,727      | -29%             | 698           |
| Other Reported Products:      |   |             |               |            |                  |               |
| AGGRASTAT                     | 1%                                      | 67          | N/A           | -          | 1%               | 67            |
| ARCOXIA                       | 18%                                     | 192         | N/A           | -          | 18%              | 192           |
| CANCIDAS                      | -4%                                     | 397         | -23%          | 171        | 19%              | 227           |
| COSOPT / TRUSOPT              | 15%                                     | 518         | 29%           | 226        | 6%               | 291           |
| CRIVAN / STOCRIN              | -8%                                     | 239         | -36%          | 19         | -4%              | 220           |
| EMEND                         | 61%                                     | 95          | 46%           | 74         | *                | 21            |
| INVANZ                        | 48%                                     | 99          | 40%           | 59         | 62%              | 40            |
| MAXALT                        | 16%                                     | 295         | 18%           | 192        | 13%              | 103           |
| PRIMAXIN                      | -4%                                     | 524         | -1%           | 154        | -6%              | 369           |
| PROPECIA                      | 21%                                     | 249         | 17%           | 108        | 25%              | 141           |
| PROSCAR                       | -9%                                     | 499         | -19%          | 219        | -                | 279           |
| TIMOPTIC / TIMOPTIC XE        | -9%                                     | 94          | -17%          | 7          | -9%              | 87            |
| VASOTEC / VASERETIC           | -13%                                    | 411         | N/A           | -          | -13%             | 411           |
| HEPATITIS VACCINES            | 24%                                     | 181         | 29%           | 145        | 7%               | 36            |
| VIRAL VACCINES <sup>(1)</sup> | 67%                                     | 774         | 70%           | 708        | 41%              | 66            |
| OTHER VACCINES                | 10%                                     | 221         | 20%           | 176        | -16%             | 45            |

\* 100% or over  
N/A - Not Applicable

<sup>(1)</sup> Includes new vaccine sales: Gardasil \$80m, RotaTeq \$95m, ProQuad \$146m, and Zostavax \$11m.

**TOTAL SALES: VOLUME, PRICE, EXCHANGE**

|                                   | YTD '06   | % CHG. | VOL | PX | FX  |
|-----------------------------------|-----------|--------|-----|----|-----|
| <b>TOTAL PHARMACEUTICAL SALES</b> | \$ 16,592 | 2%     | 2   | 1  | -1  |
| U.S. (\$ MM)                      | 10,027    | 8%     | 5   | 3  | N/A |
| Foreign (\$ MM)                   | 6,565     | -6%    | -2  | -2 | -2  |